Indication Of Minor Added Benefit For Aflibercept In Colorectal Cancer

Indication of considerable added benefit for overall survival / indications of greater harm from side effects The drug aflibercept (trade name: Zaltrap) has been approved in Germany since February 2013 in combination with a certain chemotherapy for adults with metastatic colorectal cancer in whom chemotherapy with oxaliplatin could not stop the disease from progressing...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Colorectal Cancer Source Type: news